Advertisement

Topics

Intra-Cellular Therapies, Inc. Company Profile

14:52 EDT 23rd September 2017 | BioPortfolio


News Articles [914 Associated News Articles listed on BioPortfolio]

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Intra-Cellular Therapies, Inc. To Contact The Firm

NEW YORK, NY / ACCESSWIRE / June 2, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") (NAS...

Pomerantz LLP: SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intra-Cellular Therapies, Inc. of Class Action Lawsuit and Upcoming Deadline - ITCI

NEW YORK, NY / ACCESSWIRE / June 16, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") (NASDAQ: IT...

FDA Clears Way for Filing on Psych Drug From Intra-Cellular, Shares Climb

The FDA has just lowered a key barrier standing between Intra-Cellular Therapies and potential approval of an experimental schizophrenia drug. Now the question is whether the mixed set of data the com...

IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 15, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") ...

APPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 28, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") ...

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 20, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") ...

EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 26, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") ...

DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 6, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") (...

PubMed Articles [2790 Associated PubMed Articles listed on BioPortfolio]

Evolution of anti-HER2 therapies for cancer treatment.

The development of HER2-directed monoclonal antibodies and tyrosine kinase inhibitors have provided benefits to cancer patients, as well as produced many insights into the biology of the ErbB receptor...

Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models.

Inter- and intra-tumour molecular heterogeneity is increasingly recognized in clear cell renal cell carcinoma (ccRCC). It may partially explain the diversity of responses to targeted therapies and the...

Intra- and Extra-cellular Proteome Analyses of Steroid-Producer Mycobacteria.

The importance of the pathogenic mycobacteria has mainly focused the omic analyses on different aspects of their clinical significance. In contrast, those industrially relevant mycobacteria have recei...

Cellular therapies in trauma and critical care medicine: Looking towards the future.

Shibani Pati and Todd Rasmussen summarize progress in preclinical research on cellular therapeutics for traumatic injury and its sequelae and discuss prospects for clinical translation.

Adipose-derived cellular therapies in solid organ and vascularized-composite allotransplantation.

Controlling acute allograft rejection following vascularized composite allotransplantation requires strict adherence to courses of systemic immunosuppression. Discovering new methods to modulate the a...

Clinical Trials [2891 Associated Clinical Trials listed on BioPortfolio]

Regenerative Cellular Therapies, Physiology, Pathology and Developmental Biology

This study aims to use tissue from deceased organ donors to investigate organ physiology, developmental biology, as well as the development of future regenerative cellular therapies. It wi...

Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate the...

Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase I trial is s...

Impact of Omega-3 Fatty Acids on Lactate

Pre- and intra-operative nutritional support in patient undergoing major surgery results in decreased morbidity and mortality. Studies investigating the role of omega-3 fatty acids in thes...

Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)

Dendritic cell-based cellular vaccine for tumor therapy has shown efficacy. This study is designed to perform a personalized clinical trial by first analyzing the expression of tumor assoc...

Companies [1133 Associated Companies listed on BioPortfolio]

Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. (ITI)

Intra-Cellular Therapies, Inc. (ITI) is a biotechnology company developing novel therapeutics for the treatment of depression, schizophrenia, Alzheimer's and Parkinson's disease and other disorders of...

Intracorp

Philadelphia-based Intracorp, a subsidiary of CIGNA Corporation, helps employers maximize their workers' compensation and disability benefits programs to enhance the well-being an...

Intra-Lock® International, Inc.

Intra-Lock® International Inc., headquartered in Boca Raton, Florida, USA, is a leading provider of innovative dental restoration solutions including a wide range of dental imp...

Aastrom Biosciences, Inc.

Founded in 1989 and with headquarters in Ann Arbor, Michigan, Aastrom Biosciences is dedicated to the development of stem cell treatments for critical cardiovascular diseases. Aastrom is currently e...

More Information about "Intra-Cellular Therapies, Inc." on BioPortfolio

We have published hundreds of Intra-Cellular Therapies, Inc. news stories on BioPortfolio along with dozens of Intra-Cellular Therapies, Inc. Clinical Trials and PubMed Articles about Intra-Cellular Therapies, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Intra-Cellular Therapies, Inc. Companies in our database. You can also find out about relevant Intra-Cellular Therapies, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record